NASDAQ: RGEN ยท Medical Instruments & Supplies
Repligen (RGEN) fair value: undervalued or overvalued?
As of 22 Sep 2026, Faircurve's model values Repligen (RGEN) at $142.83 a share. The stock last closed at $186.75, which puts the model's fair value 23.5% below the price. On the model's bands that reads as Overvalued.
Revalued . Price is the close of 22 Sep 2026. Repligen Corporation.
What price range does the model give RGEN?
The calibrated range for RGEN over 63 trading days is $165.29 to $235.15. It sits around the last close, and its width comes from the volatility that RGEN's own options imply (50% a year), calibrated weekly against realised prices (n = 2,982 past valuations, refreshed 19 Sep 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $105.00 to $192.01. In 25% of the simulations the fair value came out above the price the model ran on.
How does RGEN score on business quality?
Repligen's overall quality score is 62 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 38 | 2.4%ROIC | 3.6% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 73 | 2.67xFCF / net income | 0.97x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analyst estimate revisions. | 78 | 16.4%Revenue growth, trailing | 2.1% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 61 | 0.2%Net buybacks / market value | 0.1% |
| Balance sheetNet debt to EBITDA and interest coverage. | 75 | 0.69xNet debt / EBITDA | 5.06x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 67 | 5.5 ptsEBITDA margin downside volatility, 5y | 6.0 pts |
How does RGEN compare with similar companies?
The companies in medical instruments & supplies closest to Repligen in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| AVTR Avantor, Inc. | $14.94 | $18.27 | +22.3% | Low model confidence |
| COO The Cooper Companies, Inc. | $55.29 | $57.26 | +3.6% | Fairly valued |
| BAX Baxter International Inc. | $23.68 | $24.40 | +3.0% | Fairly valued |
| ATR AptarGroup, Inc. | $125.45 | $123.68 | -1.4% | Fairly valued |
| SOLV Solventum Corporation | $88.75 | $95.83 | +8.0% | Fairly valued |
| TFX Teleflex Incorporated | $124.90 | $127.50 | +2.1% | Low model confidence |
| MMSI Merit Medical Systems, Inc. | $87.26 | $87.45 | +0.2% | Fairly valued |
| WST West Pharmaceutical Services, Inc. | $371.09 | $331.50 | -10.7% | Fairly valued |
All medical instruments & supplies stocks ranked by gap to fair value
When does RGEN report earnings, and how has the stock reacted?
Repligen's next earnings report is scheduled for 3 Nov 2026. Companies can move their dates.
Options prices on 22 Sep 2026 imply a move of about 10.0% in either direction through the nearest expiry, about 23 days out. That is the size the market is pricing, not a direction. RGEN's 30 day implied volatility works out to about 14.4% over one month.
How RGEN moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 5.9%.
| Report date | Two session move |
|---|---|
| 28 Jul 2026 | +7.8% |
| 5 May 2026 | +6.4% |
| 24 Feb 2026 | -2.4% |
| 28 Oct 2025 | -7.8% |
| 29 Jul 2025 | +2.7% |
| 29 Apr 2025 | -4.0% |
| 20 Feb 2025 | +5.5% |
| 12 Nov 2024 | +7.9% |
Repligen at a glance
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems.
- Market value
- $10.0B
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Revenue expected, next twelve months
- $930M
- Consensus revenue growth, next fiscal year
- +12.1%
- Analysts with estimates
- 12
- Beta to the US market
- 0.96
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Repligen on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 19 Sep 2026 the model's fair value for RGEN was $139.86. As of 22 Sep 2026 it is $142.83, a change of +2.1%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Repligen's valuation
Is Repligen stock undervalued or overvalued?
On Faircurve's model, RGEN reads as Overvalued as of 22 Sep 2026. The model's fair value is $142.83 a share against a last close of $186.75, a gap of -23.5%.
What is RGEN's fair value?
$142.83 a share as of 22 Sep 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $105.00 to $192.01.
What price range does the model give RGEN?
$165.29 to $235.15 over 63 trading days. Ranges built this way held the price 60% of the time across 2,982 past valuations, refreshed 19 Sep 2026.
When does Repligen report earnings next?
The next report is scheduled for 3 Nov 2026. Companies can move their dates.
How much has RGEN moved on past earnings reports?
Across its last 8 reports the median two session move was 5.9%, ignoring direction. The largest was +7.9% around the report of 12 Nov 2024.
How confident is the model in this valuation?
Model confidence for RGEN is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.